Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
ovarian cancer
Biotech
VBL lays off 35% of staff after failure-induced stock shock
VBL Therapeutics is trimming its workforce by 35% less than two weeks after its lead asset flunked a phase 3 test.
Max Bayer
Aug 2, 2022 11:03am
Panic infects VBL investors as therapy fails phase 3 cancer test
Jul 20, 2022 6:30am
Roche pays Repare $125M to join Big Pharma peers in cancer race
Jun 2, 2022 8:27am
Investors fork out $76M for piece of Pheast's cancer therapies
Apr 26, 2022 11:00am
ImmunoGen files ovarian cancer drug with FDA after iffy results
Mar 29, 2022 10:30am
Verastem takes on debt to get RAS tumor program to finish line
Mar 28, 2022 8:30am